Nexentis Technologies Inc. Common Stock

Day range

$0.54 – $0.59

Open

$0.59

Prev close

$0.52

Volume

476.89K

Market cap

$761.84K

Shares out

2.96M

P/E

—

P/S

377.87

P/B

0.33

P/FCF

—

ROE

-755.3%

ROA

-92.5%

Debt/Equity

0.18

Div yield

0.00%

As of Oct 23, 2026

• Equity compensation grantOct 19, 2026

  On October 15, 2026, Nexentis Technologies Inc. issued ... 51,000 shares of common stock to a consultant for accounting and controller services ...; (ii) 101,549 shares ... to David Palach, its Chief Executive Officer; (iii) 51,000 shares ... to Lital Barda, its Chief Financial Officer; (iv) an aggregate of 208,639 shares ... to the Company's directors, in each case under its 2022 Share Incentive Plan.

• Listing deficiency noticeSep 3, 2026

  On August 31, 2026, Nexentis Technologies Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Capital Market notifying the Company that its stockholders' equity was no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. As reported on the Form 10-Q, the Company's stockholders' equity as of June 30, 2026 was $1,782,000.

• Auditor dismissalAug 6, 2026

  On August 6, 2026, the board of directors (the "Board") and audit committee of the Board (the "Audit Committee") of Nexentis Technologies Inc. (the "Company") approved the dismissal of Somekh Chaikin, a member firm of KPMG International ("KPMG Israel"), as its independent registered public accounting firm, effective on August 6, 2026.

• Public offeringJun 22, 2026

  On June 22, 2026, Nexentis Technologies Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain investors pursuant to which the Company agreed to sell and issue in a registered direct offering (the "Registered Direct Offering") an aggregate of 410,998 of the Company's shares of common stock (the "RD Shares") at a purchase price of $7.056 per share.

• Private placementJun 12, 2026

  In a concurrent private placement (the "Private Placement" and together with the Registered Direct Offering, the "Offerings"), the Company also agreed to issue to the same investors an aggregate of 311,876 warrants to purchase up to 311,876 shares of the Company's common stock (the "Warrants"). The Warrants are being offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") and Rule 506 of Regulation D promulgated thereunder.

Days to cover

1.0

Short interest

37.72K

Avg volume

59.27K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
  positiveGlobeNewswire Inc.· Sep 24, 2026